COMMON STOCK PURCHASE WARRANTCoya Therapeutics, Inc. • October 28th, 2022 • Pharmaceutical preparations • New York
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, ____ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date hereof (the “Initial Exercise Date”) and on or prior to 5:00 p.m. (New York City time) on _______, 2025 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Coya Therapeutics, Inc., a Delaware corporation (the “Company”), up to ____ shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
INDEMNIFICATION AGREEMENTIndemnification Agreement • October 28th, 2022 • Coya Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Indemnification Agreement (“Agreement”) is made as of _____, 2022 by and between Coya Therapeutics, Inc., a Delaware corporation (the “Company”), and _____ (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the Company and Indemnitee covering the subject matter of this Agreement.
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • October 28th, 2022 • Coya Therapeutics, Inc. • Pharmaceutical preparations • Texas
This Executive Employment Agreement (“Agreement”), dated March 14, 2022 (“Effective Date”), is between Coya Therapeutics, Inc. (the “Company”) and David Snyder (“Executive”).
MATERIAL TRANSFER AND OPTION AGREEMENT Carnegie Mellon University – Coya TherapeuticsCoya Therapeutics, Inc. • October 28th, 2022 • Pharmaceutical preparations • Pennsylvania
This Agreement (hereinafter this “Agreement”) is made and entered into this 24th day of June 2022 (“Effective Date”) by and between Carnegie Mellon University (hereinafter “Carnegie Mellon”), a Pennsylvania non-profit corporation having a principal place of business at 5000 Forbes Avenue, Pittsburgh, Pennsylvania 15213 and Coya Therapeutics, Inc., a Delaware corporation having a principal place of business at 5850 San Felipe St. Suite 500; Houston, TX 77057 (“Licensee”).
Employment Agreement AddendumEmployment Agreement • October 28th, 2022 • Coya Therapeutics, Inc. • Pharmaceutical preparations
We, the Employer and Employee, agree to the aforementioned additions to the employment contract. Any changes made here are legally binding upon signature of both parties. These changes are pursuant to the vote made by the Board regarding Howard’s executive compensation review.
